165 related articles for article (PubMed ID: 22113313)
1. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.
Guedan S; Grases D; Rojas JJ; Gros A; Vilardell F; Vile R; Mercade E; Cascallo M; Alemany R
Gene Ther; 2012 Nov; 19(11):1048-57. PubMed ID: 22113313
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
3. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
4. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
7. Replicating retroviral vectors for oncolytic virotherapy of experimental hepatocellular carcinoma.
Lu YC; Chen YJ; Yu YR; Lai YH; Cheng JC; Li YF; Shen CH; Tai CK
Oncol Rep; 2012 Jul; 28(1):21-6. PubMed ID: 22552490
[TBL] [Abstract][Full Text] [Related]
8. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
[TBL] [Abstract][Full Text] [Related]
9. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
10. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
Ryan PC; Jakubczak JL; Stewart DA; Hawkins LK; Cheng C; Clarke LM; Ganesh S; Hay C; Huang Y; Kaloss M; Marinov A; Phipps SS; Reddy PS; Shirley PS; Skripchenko Y; Xu L; Yang J; Forry-Schaudies S; Hallenbeck PL
Cancer Gene Ther; 2004 Aug; 11(8):555-69. PubMed ID: 15232601
[TBL] [Abstract][Full Text] [Related]
13. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
14. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
[TBL] [Abstract][Full Text] [Related]
15. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
16. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
[TBL] [Abstract][Full Text] [Related]
17. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force.
Tresilwised N; Pithayanukul P; Mykhaylyk O; Holm PS; Holzmüller R; Anton M; Thalhammer S; Adigüzel D; Döblinger M; Plank C
Mol Pharm; 2010 Aug; 7(4):1069-89. PubMed ID: 20550160
[TBL] [Abstract][Full Text] [Related]
18. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
19. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
20. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
